Ad is loading...
MMEAX
Price
$46.32
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
VISVX
Price
$50.61
Change
-$0.00 (-0.00%)
Updated
Nov 21 closing price
Ad is loading...

MMEAX vs VISVX

Header iconMMEAX vs VISVX Comparison
Open Charts MMEAX vs VISVXBanner chart's image
Victory Integrity Discovery A
Price$46.32
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
Vanguard Small Cap Value Index I
Price$50.61
Change-$0.00 (-0.00%)
VolumeN/A
CapitalizationN/A
MMEAX vs VISVX Comparison Chart
Loading...
View a ticker or compare two or three
VS
MMEAX vs. VISVX commentary
Nov 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MMEAX is a StrongBuy and VISVX is a Buy.

FUNDAMENTALS
Fundamentals
VISVX has more cash in the bank: 57.6B vs. MMEAX (71.1M). VISVX pays higher dividends than MMEAX: VISVX (1.90) vs MMEAX (0.39). MMEAX was incepted earlier than VISVX: MMEAX (28 years) vs VISVX (27 years). MMEAX is a more actively managed with annual turnover of: 35.00 vs. VISVX (16.00). MMEAX has a lower initial minimum investment than VISVX: MMEAX (2500) vs VISVX (3000). VISVX (30.04) and MMEAX (29.75) have marching annual gain over last year. VISVX return over 5 years is better than : 62.14 vs. MMEAX (40.78).
MMEAXVISVXMMEAX / VISVX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence28 years27 years-
Gain YTD16.11917.71291%
Front LoadN/AN/A-
Min. Initial Investment2500300083%
Min. Initial Investment IRAN/AN/A-
Net Assets71.1M57.6B0%
Annual Yield % from dividends0.391.9021%
Returns for 1 year29.7530.0499%
Returns for 3 years-2.1616.92-13%
Returns for 5 years40.7862.1466%
Returns for 10 years25.04109.8323%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
EFXT9.240.20
+2.21%
Enerflex Ltd
RVSN0.440.01
+1.60%
Rail Vision Ltd
CAG27.170.05
+0.18%
Conagra Brands
FULC2.97-0.02
-0.67%
Fulcrum Therapeutics
KYMR43.51-0.54
-1.23%
Kymera Therapeutics